Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

21.96 +0.17 (+0.78%)
Streaming Delayed Price Updated: 3:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 Next >
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry 
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.